IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO
[Chongqing, China – July 26, 2025] The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic conferences in the ophthalmology field, CCRVO brought together leading ophthalmic clinicians and vision science research teams from China, Europe, and the United States, focusing on cutting-edge topics in clinical translation of ophthalmology.
Ms. Gao Jun, Clinical Medical Director at IVIEW Therapeutics (Zhuhai), presented the company’s latest research findings, “Advancing First-in-Human Gene Therapy for Glaucoma”, at the Inherited Ocular Diseases / Gene Therapy sub session on July 26. This marked the first disclosure to China’s ophthalmology community of new research progress on the company’s innovative gene therapy candidate GVB-2001.
1. Breakthrough Gene Therapy for Ophthalmology: Innovative Rho Pathway Targeting Design
In her presentation, Ms. Gao detailed the innovative design of GVB-2001 (scAAV2.dnRhoA): a single intracameral injection delivering a transgene that inhibits the Rho signaling pathway, targeting the trabecular meshwork to enhance aqueous humor outflow and achieve sustained intraocular pressure (IOP) reduction. This therapy overcomes genetic subtype limitations and is applicable to all patients with primary open-angle glaucoma (POAG), offering the potential to address the limitations of current symptomatic treatments.
Preclinical animal studies confirmed its long-lasting IOP-lowering effect—demonstrating a dose-dependent, stable reduction in IOP that was maintained across low-, medium-, and high-dose groups through Day 56.
2. Safety Validation and Accelerated Clinical Translation
Preclinical toxicology studies also confirmed the therapy’s safety profile: the high-dose group exhibited good tolerability, only mild anterior chamber inflammatory responses were observed, and histopathological examinations revealed no structural abnormalities.
Ms. Gao noted, “The ability to achieve long-lasting IOP reduction with a single administration lays a solid foundation for clinical application.” Based on these findings, the First-in-Human (FIH) investigator-initiated trial (IIT) of GVB-2001 injection for the treatment of POAG has been initiated at the Department of Ophthalmology, The First Affiliated Hospital of Soochow University, and is currently in the subject recruitment phase.
3. Pioneering a New Path for Ophthalmic CGT Commercialization
This advancement comes at a pivotal moment in the global development of ophthalmic cell and gene therapy (CGT). The successful development of GVB-2001 highlights China’s unique advantages in the field—leveraging abundant clinical resources, precise surgical techniques, and engineering capabilities, and accelerating translational breakthroughs through novel delivery technologies and differentiated indication selection.
These achievements echo a core perspective raised at the 2025 VBEF Summit: the eye’s inherent immune privilege and blood-ocular barrier present unique opportunities for gene therapy.
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. We invest in novel mechanisms of action and differentiated drug delivery platforms to create therapies with superior clinical profiles that address significant unmet medical needs. Our pipeline includes small molecules and gene therapies for dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. The U.S. headquarters is located in Cranbury, New Jersey, with 11,045 square feet of combined laboratory and office space in the Princeton area.
For additional information, please visit www.iviewtherapeutics.com
Media Contact:
Wei Wang, PhD, Head of Operations
Email: weiwang@iviewinc.com